Document is current
Any future updates will be listed below
-
Authors
Rasool, Reyaz ur
O’Connor, Caitlin M.
Das, Chandan Kanta
Alhusayan, Mohammed
Verma, Brijesh Kumar
Islam, Sehbanul
Frohner, Ingrid E. https://orcid.org/0000-0002-0200-449X
Deng, Qu https://orcid.org/0000-0003-0030-2511
Mitchell-Velasquez, Erick
Sangodkar, Jaya
Ahmed, Aqila
Linauer, Sarah
Mudrak, Ingrid
Rainey, Jessica https://orcid.org/0000-0003-3447-854X
Zawacki, Kaitlin P.
Suhan, Tahra K.
Callahan, Catherine G.
Rebernick, Ryan
Natesan, Ramakrishnan
Siddiqui, Javed
Sauter, Guido
Thomas, Dafydd
Wang, Shaomeng
Taylor, Derek J.
Simon, Ronald
Cieslik, Marcin
Chinnaiyan, Arul M. https://orcid.org/0000-0001-8743-7480
Busino, Luca https://orcid.org/0000-0001-6758-9276
Ogris, Egon
Narla, Goutham https://orcid.org/0000-0003-4098-4203
Asangani, Irfan A. https://orcid.org/0000-0001-5381-1702
- License Information
-
More Information
Article History
Received: 3 January 2023
Accepted: 9 August 2023
First Online: 29 August 2023
Competing interests
: G.N. has an equity interest in RAPPTA Therapeutics and serves as consultants, along with C.O. E.O. serves as a consultant to Millipore Corporation and RAPPTA Therapeutics and has option interests in RAPPTA Therapeutics. The Medical University of Vienna and the Regents of The University of Michigan on behalf of the authors EO and GN have filed patent WO2021148681A1 on the PP2A methyl-C subunit specific monoclonal antibody 7C10-C5 with the title: Antibodies specifically binding the carboxymethylated catalytic subunit of protein phosphatase 2A. All other authors declare no competing interests.
